-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Junshi Biotech's announcement, the company's product treprilizumab injection combined with viducitumab for use in locally advanced or metastatic urothelial cancer expressed by HER2 was successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. The new medical insurance catalogue will be officially implemented on January 1, 2027, and the agreement is valid from January 1, 2027 to December 31, 2027. As of the announcement disclosure date, all 13 indications approved for marketing by Tuoyi® in mainland China have been included in the national health insurance catalogue.
Share
Listen to the news
According to Junshi Biotech's announcement, the company's product treprilizumab injection combined with viducitumab for use in locally advanced or metastatic urothelial cancer expressed by HER2 was successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. The new medical insurance catalogue will be officially implemented on January 1, 2027, and the agreement is valid from January 1, 2027 to December 31, 2027. As of the announcement disclosure date, all 13 indications approved for marketing by Tuoyi® in mainland China have been included in the national health insurance catalogue.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending